The $195 Million Voucher: How Denali Turned a Hunter Syndrome Approval Into a Pipeline War Chest

Picture a regulatory affairs team in South San Francisco on March 25, 2026, watching an FDA press announcement load on a browser. The drug is AVLAYAH, a biologic for Hunter syndrome in children. The disease affects fewer than 2,000 patients in the United States. The approval is accelerated. On its face, this is a narrow win in an ultra-rare corner of pediatric medicine. But tucked into the regulatory package is something that has nothing to do with Hunter syndrome at all: a Rare Pediatric Disease Priority Review Voucher, a detachable financial instrument that Denali Therapeutics can sell to any large pharma sponsor who wants to shave six months off an FDA review clock on an entirely different drug. Three months later, that voucher sells for $195 million.

That number deserves context. When BioMarin sold a PRV to Regeneron in July 2014 after the FDA approval of VIMIZIM for a related MPS disorder, it fetched $67.5 million. Between 2012 and April 2018, seven PRV sales totaled a combined $1.2 billion across the entire program, an average of roughly $171 million per transaction. Denali just cleared that average on a single voucher, in a market where the average PRV price between 2020 and November 2024 was $107 million, with 2026 prices spiking to a range of $180 million to $205 million. The voucher market has more than doubled in a decade, and Denali just monetized near the top of the current range.

The through-line here is not about Hunter syndrome, and it is not really about vouchers. It is about a company that built a platform technology capable of crossing the blood-brain barrier, used a rare pediatric disease approval to clinically validate that platform, and then converted regulatory recognition into $195 million of non-dilutive capital to fund the next eight programs in the queue. The PRV is the punctuation mark on a strategy that started years earlier in the lab.

The Platform That Made the Voucher Worth This Much

Start with the science, because the commercial logic flows from it. The blood-brain barrier has defeated more drug development programs than any single disease target. Most large molecules, including the antibodies and enzymes that work beautifully against peripheral targets, simply cannot cross it in therapeutically relevant concentrations. Denali’s TransportVehicle platform is an engineered Fc domain that hijacks natural receptor-mediated transcytosis, binding to transferrin receptor and CD98 heavy chain transporters expressed at the barrier and riding them into brain tissue. In animal models, antibodies and enzymes built on this platform achieve more than 10- to 30-fold greater brain exposure than unconjugated equivalents. For oligonucleotides, the multiplier reaches more than 1,000-fold greater brain exposure in primates compared to systemically delivered oligonucleotides without the technology.

Those are preclinical numbers, and preclinical numbers have disappointed this industry more times than anyone wants to count. Which is exactly why the March 25, 2026 accelerated approval of AVLAYAH matters beyond Hunter syndrome itself. AVLAYAH is tividenofusp alfa-eknm, an enzyme replacement therapy for the neurologic manifestations of MPS II, approved for presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. It is the first FDA-approved biologic specifically designed to cross the blood-brain barrier via transferrin receptor-mediated transport. The platform is now clinically validated. Every subsequent program in the Denali pipeline carries a different risk profile than it did on March 24.

That de-risking is what makes the $195 million feel rational rather than exuberant.

Denali now has five TransportVehicle-enabled programs in active clinical development. DNL126 targets Sanfilippo syndrome type A, a neurodegenerative lysosomal storage disorder with no approved treatment. DNL593 is a progranulin replacement therapy for GRN-related frontotemporal dementia, a genetically defined neurodegenerative disease where the causative mechanism is well characterized but therapeutic delivery to the brain has historically been intractable. DNL952 is advancing in Pompe disease, and DNL628 is an oligonucleotide TransportVehicle program targeting MAPT, a tau-related mechanism in Alzheimer’s disease. Beyond that cohort sits a wave of IND-enabling programs: DNL921 for Alzheimer’s disease, DNL111 for Parkinson’s disease and Gaucher disease, DNL622 for Hurler syndrome, and DNL422, another Parkinson’s program targeting alpha-synuclein. That is a portfolio with eight programs riding a platform that now has one FDA approval on its record.

Rare disease approvals generate PRVs. PRVs generate capital. Capital funds the next rare disease program, which may generate another PRV. The loop is not accidental.

What a Voucher at $195 Million Actually Signals

Here is the counterintuitive read on the PRV market that most coverage misses. The conventional assumption is that voucher prices rise because large pharma is becoming more willing to pay for speed. That is partially true, but the deeper driver is something else: the universe of genuinely launch-ready blockbuster programs that benefit from a six-month priority review acceleration has gotten smaller, not larger, as FDA review times have compressed and breakthrough therapy designations have proliferated. A sponsor paying $195 million for a PRV in 2026 is paying that price specifically because they have a drug where six months of additional market exclusivity translates into more than $195 million of incremental revenue before a competitor or biosimilar enters. That calculus applies to a shrinking list of programs, which means competition for vouchers at the top end is intensifying even as the number of vouchers issued has grown.

The GAO and academic critics of the PRV program have argued that financial incentives built around voucher monetization risk distorting R&D priorities, pulling resources toward diseases that generate PRVs rather than diseases with the greatest unmet need. That critique has merit as a systemic concern. But at the company level, Denali’s situation is a reasonable rebuttal: AVLAYAH treats a disease with no prior BBB-penetrant biologic, and the $195 million in proceeds will fund programs for Sanfilippo syndrome, frontotemporal dementia, and Alzheimer’s disease, none of which qualify as low-unmet-need targets.

Alexander Schuth, Denali’s Chief Operating and Financial Officer, described the proceeds as arriving “at a pivotal moment” to “fuel the advancement and acceleration of our broad clinical pipeline.” The language is careful but the commercial logic underneath it is blunt: Denali is transitioning from a pure development-stage company into a commercial-stage company with a validated platform, and doing so without diluting shareholders to fund the next phase of clinical spend.

The Race the Voucher Just Funded

Sanfilippo syndrome type A, the target of DNL126, is a lysosomal storage disorder caused by SGSH enzyme deficiency that progressively destroys neuronal function in children, typically causing death in the second or third decade of life. There is no approved treatment. The disease is devastating, the patient population is small, and the development economics have historically been forbidding precisely because getting any enzyme into the brain at therapeutic concentrations has been unsolved. With AVLAYAH’s approval as proof of concept, DNL126’s Phase 1/2 data will be read against a validated delivery mechanism, not an unproven hypothesis.

GRN-related frontotemporal dementia, the target of DNL593, represents a different kind of commercial opportunity. Frontotemporal dementia is the most common form of dementia in patients under 60, and the GRN-mutation subgroup is genetically defined, meaning patient identification is relatively tractable compared to broader Alzheimer’s populations. DNL628’s MAPT-targeting oligonucleotide approach for Alzheimer’s disease sits at the far end of the risk spectrum, but the 1,000-fold brain exposure improvement Denali reports for oligonucleotide TransportVehicle constructs in primates is a number that Alzheimer’s drug developers would have considered science fiction five years ago.

The buyer of Denali’s $195 million PRV has not been disclosed. That anonymity is standard in these transactions, but the identity matters commercially: whoever purchased it has a drug they believe generates more than $195 million in value from a six-month acceleration, and the closing is still subject to Hart-Scott-Rodino review, meaning the deal is significant enough to trigger antitrust notification thresholds. The closing timeline will tell part of the story about which program is on the other end of this transaction.

Meanwhile, Denali sits with a validated BBB delivery platform, a commercial product on the market, eight additional programs behind it, and $195 million arriving in its treasury before the summer ends. The PRV program was designed by Congress in 2007 to incentivize rare pediatric drug development. Whether it works as intended is a policy question. Whether Denali has mastered it as a strategic instrument is not a question at all.

References

1. GlobeNewswire / Denali Therapeutics — “Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million” (June 18, 2026)
2. FDA — “FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome” (March 25, 2026)
3. BioMarin Pharmaceutical — “BioMarin Sells Priority Review Voucher for $67.5 Million” (July 30, 2014)
4. Health Affairs — PRV program analysis: thirteen PRVs awarded 2012–2018, seven sold for total $1.2 billion
5. Endpoints News — “The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way”
6. Denali Therapeutics — Pipeline and Platform Overview
7. PubMed Central / NIH — GAO and academic analysis of PRV program incentive distortion concerns